Research programme: P450RAI inhibitors - OPKO Health

Drug Profile

Research programme: P450RAI inhibitors - OPKO Health

Alternative Names: P450RAI inhibitors research programme - Cytochroma

Latest Information Update: 21 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytochroma
  • Class
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute promyelocytic leukaemia

Most Recent Events

  • 04 Mar 2013 Cytochroma has been acquired by OPKO Health
  • 17 Dec 2002 Discontinued - Preclinical for Acute promyelocytic leukaemia in Canada (unspecified route)
  • 22 Sep 2000 A US patent has been issued to Cytochroma for Retinoid Metabolizing Protein
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top